Qui Tam

Effect on Off-Label Marketing in the 2010 Budget Details?

By Nolan and Auerbach

The Department of Health and Human Services recently released its budget proposal for 2010. As it relates to the FDA, HHS is looking to build

on the  $1.1billion included in the recovery Act for comparative effectiveness research.  The funds requested will continue efforts to produce state-of-the-science information on what medical treatments work best for a given condition.

Not only will these  findings enhance medical decision-making by patients and their physicians,  they will likely  close the door a little bit more to the success of off-label marketing of pharmaceuticals for indications that have little to no science to back up the claims of efficacy. Physicians will hopefully have a readily available source from which to compare treatments and drugs.

Full post as published by Pharma 101 - Pharmaceutical Fraud on June 09, 2009 (boomark / email).